Delivery Order SPE2DB24D9248-SPE2DB24FGRDD
Award Date
9/19/24
Potential Completion Date
10/10/24
Potential Value
$8.6K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the supply of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA). The award has a ceiling value of $7,146.90 and is a firm fixed-price delivery order contract with an ultimate completion date of August 28, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications and medical supplies to support the recurring...
This federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS. The firm fixed-price contract has a ceiling value of $8,331.72 and a period of performance through July 7, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $5,002.83 for the procurement of NEXPLANON 68 MG IMPLANTS. The contract is a firm fixed-price award with no set-aside designation, issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain program. DMS Pharmaceutical Group specializes in supplying a wide range of pharmaceutical products and medical supplies to the Department of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA) under the Medical Supply Chain program. The firm fixed-price delivery order, valued at $7,146.90, has an ultimate completion date of September 19, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications, including branded and generic...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of NEXPLANON 68 MG IMPLANTS, with a ceiling value of $7,146.90 and a period of performance through September 27, 2024. The award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of NEXPLANON 68 MG IMPLANTS to the U.S. Department of Defense (DoD) and Defense Logistics Agency (DLA) Medical Supply Chain. The award, valued at $8,576.28, is a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order valued at $8,576.28. The contract is for the supply of NEXPLANON 68 MG IMPLANTS to the Department of Defense's Medical Supply Chain. The award does not have a set-aside designation. This contract is issued under a larger Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group Inc. holds with the Defense Logistics Agency (DLA) under the SPE2DB program. The...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $8,331.72 firm-fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS, with a completion date of June 26, 2025. DMS Pharmaceutical Group is an established federal contractor, holding a significant Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999 through November 2026. This IDC enables the DLA to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $8,576.28 for the supply of NEXPLANON 68 MG IMPLANTS. The award was made by the Defense Logistics Agency (DLA) under the SPE2DB program, which is an indefinite delivery contract (IDC) with a ceiling value of up to $499,999,999 that runs through December 31, 2025. DMS Pharmaceutical Group holds this single-award IDC to provide a comprehensive range of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The firm-fixed-price delivery order, valued at $10,414.65, has a completion date of July 16, 2025. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler that specializes in supplying a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter...